Latest news

• MSD launches antibiotic combo Recarbrio in UK

  Earlier this year, the European Commission approved Recarbrio (imipenem/cilastatin/relebactam) for the treatment of infections caused by aerobic Gram-negative organisms in adults with limited treatment options. ... The regimen combines MSD’s

• Shionogi’s novel antibiotic trial data published in The Lancet

  the older antibiotic imipenem/cilastatin.

• Shionogi's Gram-negative antibiotic launches in the UK

  the older antibiotic imipenem/cilastatin.

• FDA accepts priority review for Merck’s antibiotic combo Recarbrio

  The  regimen combines Merck’s imipenem/cilastatin duo – sold as Primaxin as a broad-spectrum antibiotic – with a new beta lactamase inhibitor called relebactam that is designed to restore the susceptibility ... A pivotal phase 3 trial of Recarbrio

• Shionogi scores FDA approval for new cUTI antibiotic

  the Fetroja treatment arm compared to the older antibiotic (imipenem/cilastatin) arm.